22nd Century Group, Inc. (XXII): Price and Financial Metrics

22nd Century Group, Inc. (XXII): $0.86

0.02 (-2.45%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

F

Add XXII to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#276 of 341

in industry

XXII Price/Volume Stats

Current price $0.86 52-week high $110.24
Prev. close $0.88 52-week low $0.58
Day low $0.84 Volume 128,300
Day high $0.91 Avg. volume 853,023
50-day MA $0.98 Dividend yield N/A
200-day MA $3.18 Market Cap 7.09M

XXII Stock Price Chart Interactive Chart >


22nd Century Group, Inc. (XXII) Company Bio


22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The company was founded in 1998 and is based in Clarence, New York.


XXII Latest News Stream


Event/Time News Detail
Loading, please wait...

XXII Latest Social Stream


Loading social stream, please wait...

View Full XXII Social Stream

Latest XXII News From Around the Web

Below are the latest news stories about 22ND CENTURY GROUP INC that investors may wish to consider to help them evaluate XXII as an investment opportunity.

22nd Century Group Completes Sale of Hemp/Cannabis Franchise

Sale Will Significantly Reduce Operating Expenses, Ultimately Reduce Debt by $5.2 Million Buffalo, New York--(Newsfile Corp. - December 28, 2023) - 22nd Century Group, Inc. (NASDAQ: XXII) (the "Company" or "22nd Century"), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced it has closed the sale of its hemp/cannabis operations. The transaction will significantly reduce the Company's operating costs going forward, a key step in

Yahoo | December 28, 2023

22nd Century Group's Senior Lender Approves Sale of Hemp/Cannabis Franchise on Improved Terms

Sale and Related Actions Ultimately Expected to Reduce Debt Principal by $5.2 Million Buffalo, New York--(Newsfile Corp. - December 14, 2023) - 22nd Century Group, Inc. (NASDAQ: XXII) (the "Company" or "22nd Century"), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced it has secured the consent of its senior lender under the terms of its Senior Secured Credit Facility for the previously announced sale of its GVB ...

Yahoo | December 14, 2023

22nd Century Secures $3.2 Million to Date in Warrant Exchange Transaction

Newly Appointed CEO Leading Restructuring to Focus on Tobacco Industry Operations, Reduce CostsBUFFALO, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company”), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the exercise of warrants by certain holders pursuant to its previously announced warrant inducement offering. During the inducement period, certain holders of the Company’s exist

Yahoo | December 4, 2023

22nd Century Appoints Larry Firestone as Chairman and CEO

Turnaround Veteran to Focus on Unlocking Shareholder Value in Tobacco AssetsBUFFALO, N.Y., Nov. 29, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (“22nd Century” or the “Company”), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the appointment of Lawrence (Larry) Firestone as the Company's Chairman and Chief Executive Officer. Nora Sullivan, former Chair of the Board, commented, “Larry is a seasoned exec

Yahoo | November 29, 2023

22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchise

Sale Expected to Result in Immediate and Significant Reduction in Operating Costs and Cash RequirementsBUFFALO, N.Y., Nov. 27, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company” or “22nd Century”), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced it has reached an agreement to sell substantially all of its GVB Biopharma (“GVB”) hemp/cannabis operations to Specialty Acquisition Corporation

Yahoo | November 27, 2023

Read More 'XXII' Stories Here

XXII Price Returns

1-mo 42.79%
3-mo -46.91%
6-mo -68.60%
1-year -98.04%
3-year -99.88%
5-year -99.81%
YTD -71.13%
2023 -98.65%
2022 -70.21%
2021 40.45%
2020 100.00%
2019 -55.82%

Continue Researching XXII

Here are a few links from around the web to help you further your research on 22nd Century Group Inc's stock as an investment opportunity:

22nd Century Group Inc (XXII) Stock Price | Nasdaq
22nd Century Group Inc (XXII) Stock Quote, History and News - Yahoo Finance
22nd Century Group Inc (XXII) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!